公开(公告)号：US20190263832A1

公开(公告)日：2019-08-29

申请号：US16256773

申请日：2019-01-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20240360156A1

公开(公告)日：2024-10-31

申请号：US18592897

申请日：2024-03-01

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I):




wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20200317692A1

公开(公告)日：2020-10-08

申请号：US16827316

申请日：2020-03-23

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20180162875A1

公开(公告)日：2018-06-14

申请号：US15845621

申请日：2017-12-18

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20170022222A1

公开(公告)日：2017-01-26

申请号：US15289650

申请日：2016-10-10

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

Abstract translation: 其中每个符号如说明书中所定义，或其盐，其具有AMPA（α-氨基-3-羟基-5-甲基-4-异恶唑丙酸）受体增强作用。 本发明的化合物可用作抑郁症，精神分裂症，阿尔茨海默病或注意缺陷多动障碍（ADHD）等的预防或治疗药物。

公开(公告)号：US20150073137A1

公开(公告)日：2015-03-12

申请号：US14540699

申请日：2014-11-13

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US20150353578A1

公开(公告)日：2015-12-10

申请号：US14804935

申请日：2015-07-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

Abstract translation: 提供由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐，其具有AMPA（α-氨基-3-羟基-5-甲基-4-异恶唑丙酸）受体 增效作用 本发明的化合物可用作抑郁症，精神分裂症，阿尔茨海默病或注意缺陷多动障碍（ADHD）等的预防或治疗药物。

公开(公告)号：US20140080817A1

公开(公告)日：2014-03-20

申请号：US13774707

申请日：2013-02-22

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

Abstract translation: 提供由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐，其具有AMPA（α-氨基-3-羟基-5-甲基-4-异恶唑丙酸）受体 增效作用 本发明的化合物可用作抑郁症，精神分裂症，阿尔茨海默病或注意缺陷多动障碍（ADHD）等的预防或治疗药物。

公开(公告)号：US20130184266A1

公开(公告)日：2013-07-18

申请号：US13774635

申请日：2013-02-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masakuni KORI ,  Toshihiro IMAEDA ,  Shinji NAKAMURA ,  Masashi TOYOFUKU ,  Eiji HONDA ,  Yasutomi ASANO ,  Osamu UJIKAWA ,  Michiyo MOCHIZUKI

IPC: C07D513/04

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.